DEALS: GSK licenses Genmab's HuMax-DC20 for $2.1B


GSK licenses Genmab's HuMax-DC20 for $2.1B


DEALS

WHO

WITH

WHAT

SCOOP

GlaxoSmithKline

Genmab

$2.1B licensing deal

The deals is for Genmab's HuMax-CD20 antibody for leukemia.

Amgen

Cytokinetics

$675M development deal

The deal covers CK-1827452, which triggers a protein that causes the heart to contract as it pumps blood.

Forest Laboratories

Cerexa

$480M buyout

Forest gains development and marketing rights for three antibiotics, including one--ceftaroline acetate--which is poised to begin a late-stage trial for skin infections.

Vectura Group

Unnamed company

$63M development pact

Vectura has been working on a copycat version of Glaxo's best selling asthma drug Advair, which loses patent protection in 2010.

Bristol-Myers Squibb

Exelixis

$60M development deal

Exelixis is responsible for selecting small molecule drugs for specific targets while BMS has the right to choose up to three candidates for three targets.

GlaxoSmithKline

Praecis Pharmaceuticals

$54.8 buyout

Praecis will provide chemical-synthesis and screening technology that will GSK will use with it's own discovery capabilities.

Genentech

Exelixis

$40M development pact

Genentech and Exelixis have agreed to a global development pact for XL-518, an MEK-inhibitor for tumors.

Genentech

Altus

$30M development deal

The pact covers ALTU-238, an experimental human growth hormone being developed as a once-weekly therapy.

Centocor

FivePrime Therapeutics

$15M collaboration pact

FivePrime Therapeutics will work with Centocor Research on the development of new therapies for osteoarthritis and pulmonary fibrosis.

PerkinElmer

Euroscreen Products

Buyout

Euroscreen markets products to laboratories engaged in drug discovery work. This is ElmerPerkin's seventh acquisition of the year.

Otsuka Pharmaceutical

Bristol-Myers Squibb

Licensing deal

Otsuka Pharmaceutical has licensed the Japanese rights to Bristol-Myers Squibb's saxagliptin, being studied for the treatment of Type 2 diabetes.

Schering-Plough

Valeant Pharmaceuticals and Metabasis Technologies

Licensing deal

Schering-Plough has licensed the experimental pradefovir for chronic hepatitis B. Valeant licensed the drug from Metabasis six years ago.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.